Summary
51 / 100 · Bulios Score
What speaks for it
- Out of every 100 USD of revenue, 15 USD is left as net profit.
- It holds more cash than debt: $2.78M against $762.0K.
- You pay 0.0 USD for 1 USD of yearly profit, little for its sector.
What to watch
- Revenue fell by 9.6% a year over the last 3 years.
- It reports a profit, yet spends more cash than it brings in.
- It passes only 3 of the 9 points of the Piotroski financial health test.
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Score in detailPrice
Is it expensive?
Looks cheapToday you pay 0.0 USD for 1 USD of yearly profit.
Valuation in detailIs it growing?
It is shrinkingRevenue (USD)
Diluted EPS (USD)
- Analyst estimate
Revenue fell by 9.6% a year over the last 3 years.
Growth in detailDoes it make money?
ReasonablyWhere 100 USD of revenue goes
- Cost of sales 4.9 USD
- Research and development 52 USD
- Sales and administration 25 USD
- Taxes and other 5.3 USD
- Net profit 15 USD
Net profit, industry median (Biotechnology) -7.3 USD
Out of every 100 USD of revenue, 15 USD is left as net profit.
Profitability in detailIs it financially healthy?
YesOver the last 12 months it spent more cash than it brought in. It holds more cash than debt.
Financial health in detailDoes it pay a dividend?
NoIt pays no dividend.
Dividends in detailWhat do analysts expect?
Neutral- Buy 2
- Hold 4
- Sell 0
Today's price within the analysts' price targets
The average target of $6 is 2,999,900% above today's price. 33% of the analysts recommend buying.
Analysts in detailWhat does it earn on?
Fiscal year 2024By product
- Milestones 100%
By region
The company reports no revenue by region.
Milestones brings in 100% of revenue.
Segments in detail